Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Long-Term Investments for 5 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 55.15% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 55.15% decrease, with the full-year FY2025 number at $3.3 million, down 55.15% from a year prior.
  • Long-Term Investments was $3.3 million for Q4 2025 at Rhythm Pharmaceuticals, up from $2.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $18.4 million in Q1 2022 to a low of $2.2 million in Q2 2025.
  • A 5-year average of $11.8 million and a median of $13.3 million in 2024 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 48.26% in 2022, then tumbled 82.59% in 2025.
  • Rhythm Pharmaceuticals' Long-Term Investments stood at $11.8 million in 2021, then skyrocketed by 40.96% to $16.7 million in 2022, then decreased by 9.94% to $15.0 million in 2023, then plummeted by 51.16% to $7.3 million in 2024, then tumbled by 55.15% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Long-Term Investments are $3.3 million (Q4 2025), $2.5 million (Q3 2025), and $2.2 million (Q2 2025).